Sign Up
Stories
Cordis and Boston Scientific: Advancements in Coronary and Peripheral Artery Disease Treatment
Share
Advanced Technology Saves Patient's Life
CSL's Disappointing Trial Results
Deep Vein Thrombosis Market Set for Grow...
Overview
API
Cordis enrolls the first patient in SELUTION4DeNovo IDE trial, a coronary de novo study for SELUTION SLR Drug-Eluting Balloon (DEB), while Boston Scientific reports positive results from its drug-coated balloon in treating patients with repeat blockages. Cordis completes patient enrollment in SELUTION SLR SUCCESS PTA Study, a large post-market study evaluating the safety, efficacy, health economics, and patient-reported quality-of-life data of the SELUTION SLR Drug-Eluting Balloon (DEB) in treating peripheral artery disease (PAD). Cordis acquires Swiss-based MedAlliance, adding MedAlliances sustained sirolimus drug-eluting balloon to its product line.
Ask a question
How might Cordis' acquisition of MedAlliance influence the competitive landscape in the interventional cardiovascular and endovascular technology market?
How might the successful completion of patient enrollment in SELUTION SLR SUCCESS PTA Study impact the approval of the SELUTION SLR Drug-Eluting Balloon (DEB) in the US?
What are the potential implications of Boston Scientific's positive results from its drug-coated balloon for the treatment of patients with repeat blockages?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage